Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license ...
San Francisco-based Mendra, a biopharma aiming to advance promising therapies for rare disease medicines, has announced its ...
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have said they will award $60 million in new grant funding over ...
UK pharma major GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults ...
US clinical-stage biotech Corxel Pharmaceuticals, dedicated to developing innovative therapies for patients with ...
Texas, USA-based IntraBio revealed that the European Commission granted marketing authorization to Aqneursa (levacetylleucine ...
DelveInsight says the cystinosis treatment market across the USA, EU4, UK and Japan totaled about $250 million in 2024, with ...
US healthcare company Sagebrush Health Services, a non-profit organization serving more than 10,000 Nevada patients, has ...
US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...
Menkes disease is a rare, X-linked genetic disorder caused by mutations in the ATP7A gene, which impair copper transport within the body. If left untreated, this defect leads to critically low copper ...
Resolve M Therapeutics has exited stealth, pitching a discovery platform designed to engage “pro-resolution” immune responses that could help restore immune balance in chronic inflammatory and ...
French drugmaker Ipsen announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback